Residents' Association Werdenberg


Understanding Pfizer Sildenafil 50mg Dosage

Sildenafil > pfizer sildenafil 50


REVATIO Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration. Concomitant administration of potent CYP3A inducers is expected to cause substantial decreases in plasma levels of sildenafil.

  • Pfizer sildenafil 50mg is often prescribed after assessing cardiovascular health.
  • It is important to follow dosing instructions to prevent side effects.
  • Sildenafil is sometimes used off-label for other medical conditions.
  • Men should seek emergency help for prolonged erections lasting over 4 hours.
  • Use of sildenafil in combination with other ED treatments should be guided by a doctor.
  • The medication can cause low blood pressure in some individuals.
  • Adherence to medical advice ensures optimal treatment results.
  • Extended use without medical supervision is not recommended.

Population pharmacokinetic analysis of data from patients in clinical trials indicated approximately 3-fold the sildenafil clearance when it was co-administered with mild CYP3A inducers. The mean reduction of sildenafil (80 mg three times a day) bioavailability when co-administered with epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations.

  • Erectile dysfunction treatments like Pfizer sildenafil 50mg focus on enhancing intimacy.
  • It does not protect against sexually transmitted infections.
  • Lifestyle changes such as exercise and healthy diet can improve ED.
  • Consult a healthcare provider before starting sildenafil if on other meds.
  • Sildenafil's effects typically last about 4-6 hours.
  • It is not a cure but a temporary solution for ED symptoms.
  • Avoid recreational drugs that may interact negatively with sildenafil.
  • Inform your doctor of all medications to prevent adverse interactions.

Therefore, the slight decrease of sildenafil exposure in the presence of epoprostenol is not considered clinically relevant.

Country/Region Legal Status Notes
USA Prescribed medication, prescription required Completely legal with prescription
European Union Prescription-only drug Must be prescribed by a licensed physician
India Over-the-counter in some states Varies by region
Australia Prescription required Strictly regulated

Sildenafil was not carcinogenic when administered to rats for up to 24 months at 60 mg/kg/day, a dose resulting in total systemic exposure (AUC) to unbound sildenafil and its major metabolite 33- and 37-times, for male and female rats respectively, the human exposure at the RHD of 20 mg three times a day.

About the Company

Bioequivalence was established between the 20 mg tablet and the 10 mg/mL oral suspension when administered as a 20 mg single oral dose of sildenafil (as citrate). Sildenafil is cleared predominantly by the CYP3A (major route) and cytochrome P450 2C9 (CYP2C9, minor route) hepatic microsomal isoenzymes. The major circulating metabolite results from N-desmethylation of sildenafil, and is, itself, further metabolized. This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in vitro potency for PDE-5 approximately 50% of the parent drug. In healthy volunteers, plasma concentrations of this metabolite are approximately 40% of those seen for sildenafil, so that the metabolite accounts for about 20% of sildenafil's pharmacologic effects.

Does Viagra prevent ejaculation?

In patients with PAH, however, the ratio lovegra sildenafil of the metabolite to sildenafil is higher. Both sildenafil and the active metabolite have terminal half-lives of about 4 hours. After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of the administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose). REVATIO Injection: The pharmacokinetic profile of REVATIO has been characterized following intravenous administration. A 10 mg dose of REVATIO Injection is predicted to provide a pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose. Sildenafil was not carcinogenic when administered to male and female mice for up to 21 and 18 months, respectively, at doses up to a maximally tolerated level of 10 mg/kg/day, a dose equivalent to the RHD on a mg/m2 basis.

Product Dosage Quantity + Bonus Price
Viagra Generic25mg180 + 6 Pills154.93€ 147.55€
Viagra Generic100mg90 + 6 Pills129.02€ 122.88€
Kamagra100mg120 + 6 Pills330.74€ 314.99€
Viagra Generic150mg120 + 8 Pills177.58€ 169.12€
Viagra Generic50mg180 + 8 Pills158.82€ 151.26€
Viagra Generic150mg20 Pills55.02€ 52.40€
Kamagra Soft Tabs100mg12 Pills57.55€ 54.81€
Kamagra Oral Jelly100mg90 + 8 Sachets303.56€ 289.10€
Viagra Generic200mg30 + 2 Pills83.07€ 79.11€
Viagra Generic50mg90 + 6 Pills107.37€ 102.26€
Viagra Generic50mg360 + 10 Pills225.33€ 214.60€
Kamagra100mg84 + 6 Pills264.44€ 251.85€
Viagra Generic100mg180 + 8 Pills199.37€ 189.88€
Viagra Generic50mg20 Pills40.52€ 38.59€
Viagra Generic25mg60 + 4 Pills71.99€ 68.56€
Kamagra Soft Tabs100mg84 + 4 Pills233.05€ 221.95€
Viagra Generic150mg180 + 10 Pills236.46€ 225.20€

Sildenafil was negative in in vitro bacterial and Chinese hamster ovary cell assays to detect mutagenicity, and in vitro human lymphocytes and in vivo mouse micronucleus assays to detect clastogenicity.

Society and culture

Larger effects were recorded among patients receiving concomitant nitrates [see Contraindications (4)]. Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG. After chronic dosing of 80 mg three times a day to patients with PAH, no clinically relevant effects on ECG were reported. After chronic dosing of 80 mg three times a day sildenafil to healthy volunteers, the largest mean change from baseline in supine systolic and supine diastolic blood pressures was a decrease of 9.0 mmHg and 8.4 mmHg, respectively. After chronic dosing of 80 mg three times a day sildenafil to patients with systemic hypertension, the mean change from baseline in systolic and diastolic blood pressures was a decrease of 9.4 mmHg and 9.1 mmHg, respectively.

Professional resources

After chronic dosing of 80 mg three times a day sildenafil to patients with PAH, lesser reductions than above in systolic and diastolic blood pressures were observed (a decrease in both of 2 mmHg). At single oral doses of 100 mg and 200 mg, transient dose-related impairment of color discrimination (blue/green) was detected using the Farnsworth-Munsell 100-hue test, with peak effects near the time of peak plasma levels. An evaluation of visual function at doses up to 200 mg revealed no effects of REVATIO on visual acuity, intraocular pressure, or pupillometry. REVATIO is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (25–63%). When REVATIO is taken with a high-fat meal, the rate of absorption is reduced, with a mean delay in Tmax of 60 minutes and a mean reduction in Cmax of 29%. There was no impairment of fertility in male or female rats given up to 60 mg sildenafil/kg/day, a dose producing a total systemic exposure (AUC) to unbound sildenafil and its major metabolite of 19- and 38- times for males and females, respectively, the human exposure at the RHD of 20 mg three times a day. Studies of Adults with Pulmonary Arterial Hypertension Study 1 (REVATIO monotherapy (20 mg, 40 mg, and 80 mg three times a day)) A randomized, double-blind, placebo-controlled study of REVATIO (Study 1) was conducted in 277 patients with PAH (defined as a mean pulmonary artery pressure of greater than or equal to 25 mmHg at rest with a pulmonary capillary wedge pressure less than 15 mmHg). Patients were predominantly World Health Organization (WHO) functional classes II–III. Allowed background therapy included a combination of anticoagulants, digoxin, calcium channel blockers, diuretics, and oxygen. The use of prostacyclin analogues, endothelin receptor antagonists, and arginine supplementation were not permitted. Subjects who had failed to respond to bosentan were also excluded.

People who purchased Pfizer Viagra 50mg Tablet 2s also bought

Age, gender, race, and renal and hepatic function were included as factors assessed in the population pharmacokinetic model to evaluate sildenafil pharmacokinetics in patients with PAH. The dataset available for the population pharmacokinetic evaluation contained a wide range of demographic data and laboratory parameters associated with hepatic and renal function. None of these factors had a significant impact on sildenafil pharmacokinetics in patients with PAH. In patients with PAH, the average steady-state concentrations were 20–50% higher when compared to those of healthy volunteers. There was also a doubling of Cmin levels compared to healthy volunteers.

Revatio Tablets

Both findings suggest a lower clearance and/or a higher oral bioavailability of sildenafil in patients with PAH compared to healthy volunteers. Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 84% and 107% higher plasma concentrations of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy younger volunteers (18–45 years). Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively. In volunteers with mild (CLcr = 50–80 mL/min) and moderate (CLcr = 30–49 mL/min) renal impairment, the pharmacokinetics of a single oral dose of sildenafil (50 mg) was not altered. In volunteers with severe (CLcr less than 30 mL/min) renal impairment, sildenafil clearance was reduced, resulting in approximately doubling of AUC and Cmax compared to age-matched volunteers with no renal impairment. Patients with left ventricular ejection fraction less than 45% or left ventricular shortening fraction less than 0.2 also were not studied.

Disease Explanation

In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased 200 % and 79 %, respectively, in subjects with severe renal impairment compared to subjects with normal renal function. In volunteers with mild to moderate hepatic cirrhosis (Child-Pugh class A and B), sildenafil clearance was reduced, resulting in increases in AUC (84%) and Cmax (47%) compared to age-matched volunteers with no hepatic impairment. Patients with severe hepatic impairment (Child-Pugh class C) have not been studied. Sildenafil metabolism is principally mediated by the CYP3A (major route) and CYP2C9 (minor route) cytochrome P450 isoforms. Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A (IC50 greater than150 µM).

Related treatment guides

Sildenafil is not expected to affect the pharmacokinetics of liquid sildenafil citrate compounds which are substrates of these CYP enzymes at clinically relevant concentrations. The effects of other drugs on sildenafil pharmacokinetics and the effects of sildenafil on the exposure to other drugs are shown in Figure 7 and Figure 8, respectively. Population pharmacokinetic analysis of data from patients in clinical trials indicated an approximately 30% reduction in sildenafil clearance when it was co-administered with mild/moderate CYP3A inhibitors and an approximately 34% reductions in sildenafil clearance when co-administered with beta-blockers. Sildenafil exposure at a dose of 80 mg three times a day without concomitant medication is shown to be 5-fold the exposure at a dose of 20 mg three times a day. This concentration range covers the same increased sildenafil exposure observed in specifically-designed drug interaction studies with CYP3A inhibitors (except for potent inhibitors such as ketoconazole, itraconazole, and ritonavir). Patients were randomized to receive placebo (n=70) or REVATIO 20 mg (n = 69), 40 mg (n = 67) or 80 mg (n = 71) three times a day for a period of 12 weeks. They had either primary pulmonary hypertension (PPH) (63%), PAH associated with CTD (30%), or PAH following surgical repair of left-to-right congenital heart lesions (7%).

  • Sildenafil is useful in treating erectile dysfunction caused by various factors.
  • It is recommended to avoid heavy meals close to medication time.
  • Patients should be aware of potential side effects like dizziness.
  • It is important to stay hydrated but avoid excessive fluid intake when taking sildenafil.
  • Check with your doctor before discontinuing or changing dosage.
  • Sildenafil may affect concomitant use of certain psychiatric medications.
  • Adequate sexual stimulation is necessary for the medication to work effectively.
  • Always adhere to your healthcare provider's instructions for best results.

The study population consisted of 25% men and 75% women with a mean age of 49 years (range: 18–81 years) and baseline 6-minute walk distance between 100 and 450 meters (mean 343).

  • The medication's effectiveness depends on individual health and physiology.
  • Sildenafil can improve quality of life and emotional well-being.
  • Always verify medication authenticity to avoid counterfeit products.
  • Patients with liver issues should have dosage adjustments if prescribed.
  • Sildenafil is not recommended for use with certain medications like riociguat.
  • The tablets should be stored in a dry, cool place away from children.
  • Avoid using other ED drugs simultaneously with sildenafil unless advised.
  • Clear communication with your doctor ensures safe use of sildenafil.

The primary efficacy endpoint was the change from baseline at week 12 (at least 4 hours after the last dose) in the 6-minute walk distance.